2026年10月16日星期五
M
Panorama Universal
Noticias globales
[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes— 柳叶刀 Lancet[Comment] Making every vial count: fractional dosing of yellow fever vaccine— 柳叶刀 Lancet[Comment] Shortening treatment to accelerate hepatitis C elimination— 柳叶刀 Lancet[Comment] Offline: In praise of astrologers, sorcerers, and magicians— 柳叶刀 Lancet[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes— 柳叶刀 Lancet[World Report] Health in Brazil's election— 柳叶刀 Lancet[Perspectives] Shadows and interiority— 柳叶刀 Lancet[Perspectives] Beyond the battlefield: war and global health security— 柳叶刀 Lancet[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes— 柳叶刀 Lancet[Comment] Making every vial count: fractional dosing of yellow fever vaccine— 柳叶刀 Lancet[Comment] Shortening treatment to accelerate hepatitis C elimination— 柳叶刀 Lancet[Comment] Offline: In praise of astrologers, sorcerers, and magicians— 柳叶刀 Lancet[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes— 柳叶刀 Lancet[World Report] Health in Brazil's election— 柳叶刀 Lancet[Perspectives] Shadows and interiority— 柳叶刀 Lancet[Perspectives] Beyond the battlefield: war and global health security— 柳叶刀 Lancet

[Correspondence] Optimising standard of care in non-small-cell lung cancer trials

Fuente 柳叶刀 LancetAhora mismo
Resumen del contenido

We read Anwen Xiong and colleagues’ study with great interest.1 Despite the established first-line role of immune checkpoint inhibitors in advanced non-small-c…

Este sitio solo proporciona títulos e índices de resúmenes; el contenido completo y los derechos de autor pertenecen al publicador original. Haga clic en el enlace original para leerlo.

Ir al texto original
Canal al que pertenece
Salud
Región a la que pertenece
Reino Unido
Idioma original
English
Número de entrada
health-a015949f

Comments 0 comments

No comments yet. Be the first.

[Correspondence] Optimising standard of care in non-small-cell lung cancer trials · Panorama Universal